Drug Profile
ISB 1342
Alternative Names: CD38 x CD3 BEAT® 1.0 bispecific antibody; CD38/CD3 Bispecific Antibody; GBR-1342; ISB-1342Latest Information Update: 02 Feb 2024
Price :
$50
*
At a glance
- Originator Glenmark Pharmaceuticals S.A.
- Developer Glenmark Pharmaceuticals S.A.; Ichnos Sciences
- Class Antineoplastics; Bispecific antibodies; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Cytotoxic T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Multiple myeloma
- No development reported Solid tumours
Most Recent Events
- 30 Jan 2024 Glenmark Pharmaceuticals S.A. plans to initiate a phase I trial for precursor-T-cell-lymphoblastic-leukaemia-lymphoma
- 09 Dec 2023 Efficacy, adverse events and pharmacokinetics data from a phase I trial in Multiple myeloma presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)
- 13 Nov 2023 ISB 1342 is still in phase I development in Multiple-myeloma (Second-line therapy or greater) in France (IV, Infusion) (NCT03309111)